CXCL9

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
onsdag, april 10, 2024
PFS, University, Epithelium, UPMC Magee-Womens Hospital, Pancreatic cancer, Triple-negative breast cancer, Colorectal cancer, Research, Cisplatin, AIM, MD, Peritoneum, Gynecologic Oncology (journal), UPMC, Gynaecology, Disease, Liver, Patient, CXCL10, CXCL11, Reproductive Sciences, Progression-free survival, Data analysis, Neoplasm, Biomarker, CXCL9, Cancer, RNA, Ovarian cancer, Medical imaging

See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .

Key Points: 
  • See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
  • Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer ( 1 , 2 ) metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver .
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors.
  • Additionally, Keynote-100’s median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study.

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
torsdag, mars 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
lördag, mars 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Retrieved on: 
torsdag, mars 7, 2024
T cell, Glioblastoma, Arms, ICT, ICV, Traffic barrier, Toxicity, Headache, Biopsy, DSM-IV codes, Cerebrospinal fluid, City, Cancer, Central nervous system, CXCL10, TME, Cerebral edema, Dual, Hope, GBM, Safety, CXCL9, Fatigue, Hypertension, Translation, CNS, Tumor microenvironment, Patient, Arm, Spinal cord, Survival, Brain, Nature Medicine, Infrared spectroscopy correlation table, Vaccine

WORCESTER, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Key Points: 
  • MB-101 was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Mustang.
  • Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.
  • Primary endpoints were safety and feasibility, with secondary endpoints measuring therapy-related cytokine dynamics, CAR T-cell persistence and clinical outcomes.
  • Dr. Brown has a financial interest in Mustang and has previously been a paid consultant for the company.

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Retrieved on: 
måndag, november 13, 2023
Therapy, CXCL10, CXCL11, Cirrhosis, AASLD, ECS, Mouse, CXCL9, Liver, Gene expression, Messenger, Hepatocyte, FRG, Chemokine, Cell, Inflammation, Fibrosis, Vaccine, Boston

CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data from two different programs that demonstrated sustained upregulation of gene expression and coordinated pre-transcriptional downregulation of multiple genes in models of liver fibrosis and inflammation, respectively, at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.

Key Points: 
  • However, to extend their reach, we need to bidirectionally control the expression of multiple genes simultaneously,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.
  • “We believe that these new data demonstrate the power of our programmable epigenomic mRNA development candidates to control gene expression with unmatched flexibility.
  • To our knowledge, these are the first results to show how site-specific epigenomic modulation can durably upregulate the expression of a master liver regeneration gene.
  • EC-mediated induction of HNF4α expression in vivo in a mouse model of liver fibrosis led to decreased collagen deposition, a key marker of fibrosis.

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Retrieved on: 
onsdag, november 8, 2023
MSD, Society for Immunotherapy of Cancer, Plasma, AIM, NYSE, Ovarian cancer, Biomarker, Therapy, Tumor necrosis factor, Viral, TNF, Pembrolizumab, DSM-IV codes, Cisplatin, PBMC, CXCL9, Research, CXCR3, University of Pittsburgh School of Medicine, Function (mathematics), SITC, Immunotherapy, CXCL11, Perforin-1, Cancer, Annual general meeting, University, Tumor microenvironment, CXCL10, Wilfrid Sellars, TME, IP, Patient, UPMC, Pharmaceutical industry, Merck

OCALA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.

Key Points: 
  • The data was also made available at the conference in a poster presentation .
  • Sequential sampling of the IP cavity showed an increase in cellularity immediately after treatment consistent with an “acute” pro-inflammatory reaction.
  • These data show a similar profile to previously published data from Roswell Park in Stage 4 triple negative breast cancer.
  • Additionally, we hope to announce topline interim survival results from UPMC in the near future.”
    For more information about the Phase 2 clinical trial of platinum-sensitive advanced recurrent ovarian cancer utilizing Ampligen®, visit clinicaltrials.gov and reference identifier: NCT03734692.

Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

Retrieved on: 
onsdag, november 9, 2022
Union, Lung, Systemic scleroderma, Serum, Skin, Extracellular matrix, CRP, Risk, Liver, CXCL10, Fibrosis, Hospital, Nature, SEC, Biomarker, Private Securities Litigation Reform Act, Pneumonia, TEL, Population, Administration, Cirrhosis, C-reactive protein, Trial of the century, Conditional sentence, Treatment, CXCL9, Forward-looking statement, Inflammation, COVID-19, Scleroderma, PSC, Communication, CCL24, Conference, Nasdaq, Primary sclerosing cholangitis, Marketing, Research, Therapy, Safety, Adult, CMMB, Cytokine, Pharmaceutical industry, Silviculture, Patient

TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, announced that clinical data presented today showed that CM-101 was safe and well-tolerated and achieved reductions in biomarkers associated with lung inflammation and fibrogenesis in a clinical study in patients hospitalized with COVID-19-derived lung injury. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis (PSC) and systemic sclerosis (SSc).

Key Points: 
  • The presentation, Treatment with CM-101 Reduced Inflammatory & Fibrotic Biomarkers in Patients with COVID-19-Derived Lung Damage, was discussed by Chemomab co-founder and Chief Scientific Officer Dr. Adi Mor at the Union World Conference on Lung Health 2022.
  • The objective of the study was to evaluate the drug's safety and activity in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic sclerosis.
  • The open label, single arm trial enrolled 16 adult COVID-19 patients with severe respiratory involvement.
  • CM-101 exposures and target engagement profiles were similar to what Chemomab researchers have seen in previous clinical studies of CM-101.

DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology’s Annual Meeting

Retrieved on: 
onsdag, maj 18, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Genetics, Physician, Psoriasis, Population, Medicine, Private Securities Litigation Reform Act, Lecture, IPC, Overalls, U.S. Securities and Exchange Commission, Dermatology, Skin, Smart, Patient, NASDAQ, Solution, SID, Decision-making, Clinical trial, CXCL9, Research, Medicare, Method, Howell, Registry, RNA, Biomarker, Genomics, NOS2, Inflammation, Adoption, TARC, Precision medicine, Society, Security (finance), SEC, Annual report, Atopic dermatitis, Medical imaging, Pharmaceutical industry

Michael Howell, Ph.D., chief scientific officer at DermTech, presented new research that enables the differentiation of the inflammatory signatures of atopic dermatitis from psoriasis in potential clinical trial participants.

Key Points: 
  • Michael Howell, Ph.D., chief scientific officer at DermTech, presented new research that enables the differentiation of the inflammatory signatures of atopic dermatitis from psoriasis in potential clinical trial participants.
  • Titled A Novel Expression Based, Non-Invasive Method to Differentiate Atopic Dermatitis and Psoriasis, the presentation focused on the viability of conducting non-invasive skin sampling with the DermTech Smart Sticker to differentiate atopic dermatitis from psoriasis.
  • DermTech collected epidermal skin samples from patients with moderate to severe atopic dermatitis and psoriasis for this research study.
  • Using a machine-learning approach, DermTech identified a unique ratio that stratified patients into atopic dermatitis versus psoriasis.

ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
onsdag, april 13, 2022
Patient, News, Cancer, Poster, Pharmacodynamics, Medication, Pharmacokinetics, PK, U.S. Securities and Exchange Commission, Association, ANCA, Adult, Achievement, Security (finance), CD8, Hidradenitis suppurativa, CXCL9, CD80, Annual report, PD-1, Half-life, PD-L1, Private Securities Litigation Reform Act, GLOBE, Risk, Terminology, Goal, CXCL10, SAN, Progress, HS, Full, Plasma, Nasdaq, Company, CD4, SEC, Kinetics, American Association for Cancer Research, Degenerative disease, Safety, American Association, AACR, PD, Pharmaceutical industry, Palladium

SAN CARLOS, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase I clinical study of CCX559 during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Key Points: 
  • The PD-L1/PD-1 interaction is one of the major immune checkpoints that limits the ability of effector T cells to destroy cancer cells.
  • During 2021, ChemoCentryx initiated a first-in-human Phase I dose escalation study to evaluate the safety, tolerability, PK and PD of CCX559 in patients with various types of advanced cancer.
  • In this Phase I basket study, CCX559 is taken orally once per day at specified dose levels, starting at 30 mg and ranging to date to 120 mg.
  • ChemoCentryx expects to present additional findings from this ongoing Phase I study at major oncology conferences through 2022.

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell

Retrieved on: 
torsdag, mars 24, 2022
Private Securities Litigation Reform Act, Company, Cancer, PSLRA, Therapy, Date, Roswell Park Comprehensive Cancer Center, CCL5, TME, NYSE, PCR, CXCL8, CXCL10, Tumor microenvironment, AACR, Research, Doctor of Philosophy, Breast, CDT, American Association, Probability, CXCL9, Tissue, Rintatolimod, ELISA, Chemokine, American, Immunology, Association, American Association for Cancer Research, Paclitaxel, Taxane, Macrophage, CXCL11, TLR3, TaqMan, COVID-19, CTL, GLOBE, Breast cancer, Degenerative disease, CKM, Time, Lists of diseases, NK, CCL22, Patient, Disease, AIM, Medical imaging, Vaccine, MD

Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.

Key Points: 
  • Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.
  • Unexpectedly, paclitaxel treatment resulted in further elevation of granulocyte/MDSC-attractant CXCL8 and CCL22, which was reversed by the combination of paclitaxel with the CKM including Ampligen.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.